SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive: 6B1 was able to bind tumor cell lines CML/ALL BV173, AML SET-2, mantle cell lymphoma Jeko, and ovarian cancer SKOV-3 (Figure 2, A–E).